ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW 436,000
+3,000 (0.69%)
At close: Dec 15, 2025
ALTEOGEN Revenue
ALTEOGEN had revenue of 49.01B KRW in the quarter ending September 30, 2025, with 902.31% growth. This brings the company's revenue in the last twelve months to 202.18B, up 171.84% year-over-year. In the year 2024, ALTEOGEN had annual revenue of 102.85B with 6.56% growth.
Revenue (ttm)
202.18B
Revenue Growth
+171.84%
P/S Ratio
115.33
Revenue / Employee
1.27B
Employees
159
Market Cap
23.32T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | 42.43B | 13.20B | 45.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| SK bioscience | 624.03B |
| Sam Chun Dang Pharm. | 220.74B |
| LigaChem Biosciences | 159.27B |